Evidence map›Paper›PMID 41083597›Full record

ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2026

Kappa opioid receptor control of motivated behavior revisited.

Zahra Z Farahbakhsh, Cody A Siciliano

Abstract readReview
In one paragraph

Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Kappa opioid receptors mediate aversion-and it matters.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Zahra Z FarahbakhshDepartment of Pharmacology, Vanderbilt Brain Institute, Vanderbilt Center for Addiction Research, Vanderbilt University, Nashville, TN, USA.
Cody A SicilianoDepartment of Pharmacology, Vanderbilt Brain Institute, Vanderbilt Center for Addiction Research, Vanderbilt University, Nashville, TN, USA. cody.siciliano@vanderbilt.edu.ORCID http://orcid.org/0000-0001-9871-2089

Funding

Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at VanderbiltP50HD103537 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Lea K Davis · 2020 to 2026
$10.3M
VAREC Research CoreP60AA031124 · NIAAA · VANDERBILT UNIVERSITY · PI Danny G. Winder · 2024 to 2026
$7.1M
Mesocortical neuromodulation in punishment-resistant alcohol drinkingR01AA030115 · NIAAA · VANDERBILT UNIVERSITY · PI Cody Siciliano · 2022 to 2026
$2.1M
8/8: INIA Stress and Chronic Alcohol Interactions: Cross-species plasticity signatures of alcohol and stressU01AA029971 · NIAAA · VANDERBILT UNIVERSITY · PI Cody Siciliano · 2022 to 2026
$2.0M
Defining the role of cortical circuit dynamics in learning and addictionR00DA045103 · NIDA · VANDERBILT UNIVERSITY · PI SICILIANO, CODY · 2020 to 2022
$764k
Role of the kappa opioid receptor system in learning and substance use disordersF31DA056196 · NIDA · VANDERBILT UNIVERSITY · PI FARAHBAKHSH, ZAHRA · 2023 to 2024
$56k
NIAAA NIH HHS P60 AA031124NIAAA NIH HHS R01 AA030115NIAAA NIH HHS U01 AA029971NICHD NIH HHS P50 HD103537NIDA NIH HHS F31 DA056196NIDA NIH HHS R00 DA045103U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA) AA029971U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA) AA031124U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) DA04510U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) DA056196
6 · The paper itself

Abstract

Since its discovery, the kappa opioid receptor (KOR) has held the curiosity of basic and clinical researchers across disciplines. Recent advances in technologies for measuring and manipulating KOR activity have poised the field for breakthrough discoveries. As paradigms shift, it is paramount that lessons from the foundational literature are synthesized and passed forward to inform future studies. At the same time, the promise of leveraging the KOR system to improve treatment of neuropsychiatric disorders has thus far failed to materialize, highlighting the need for critical evaluation of whether current frameworks have proven reliable and generalizable. To this end, we review the physiology and pharmacology of KORs and dynorphins and their role in motivated behavior from their discovery through present day. We focus on distinct epochs within the literature and, in parallel sections, present (A) a timeline of major findings leading to the frameworks on which current research is based, and (B) critically revisit the empirical support for specific aspects of these conclusions. In particular, we highlight discrepancies which subvert the canon that KORs' essential function is to encode negative affective states. By synthesizing the foundational literature and calling into question long-standing theories of KOR function, we hope to highlight the ideas that should remain foundational moving forward and identify areas that may benefit from reconceptualization.

Indexed as

MotivationReceptors, Opioid, kappaAnimalsDynorphinsHumansDynorphinsReceptors, Opioid, kappa

Identifiers

PMID41083597
PMCPMC12708679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.